Slow Clearance of Acylated, Hybrid Thrombolytic Enzymes

Summary

Two hybrid plasminogen activators, plasmin A-chair/t-PA Bchain and plasmin A-chain/u-PA B-chain have been synthestzed and purified in sufficient yield to permit measurement of clearance in small laboratory animals. Each hybrid enzyme was reversibly acylated at the active centre to allow the pharmacokinetic profile to be followed using an activity-based method without interference from plasma inhibitors. The acylated plasmin/u-PA hybrid had a clearance half-life (t_½) in guinea pigs of approximately 80 min, whereas acyl u-PA had a t_½ of 3 min. The pharmacokinetic profile of the acylated plasmin/t-PA hybrid was measured in guinea pigs, rats and rabbits; the half-lives in all three species were 60–80 min compared to half-lives of acylated, native t-PA that were in the range 0.5–1.0 min. Thus, plasmin A-chaincontaining, acylated hybrid enzymes are cleared some 30- to 100-fold more slowly than the acylated parent activators.

Keywords

Fibrinolysis - Pharmacokinetics - Thrombolytic agents

• References

• 1 Smith RA G, Dupe RJ, English PD, Green J. Fibrinolysis with acyl enzymes: a new approach to thrombolytic therapy. Nature 1981; 290: 505-508
• 2 Rijken DC, Collen D. Purification and characterisation of the plasminogen activator secreted by human melanoma cells in culture. J Biol Chem 1981; 256: 7035-7041
• 3 Gurewich V, Pannell R, Louie S, Kelley P, Suddith RL, Greenlee R. Effective and fibrin-specific clot lysis by a zymogen precursor form of urokinase (Pro-urokinase). J Clin Invest 1984; 73: 1731-1739
• 4 Monk JP, Heel RC. Anisoylated plasminogen streptokinase activator complex (APSAC). A review of its mechanism of action, clinical pharmacology and therapeutic use in acute myocardial infarction Drugs 1987; 34: 25-49
• 5 Verstraete M, Bernard R, Bory M, Brower RW, Collen D, De Bono DP, Erbel R, Huhmann W, Lennane RJ, Lubsen J, Mathey D, Meyer J, Michels HR, Rutsch W, Schartl M, Schmidt W, Vebis R, Von Fssen R. Randomized trial of intravenous recombinant tissue- type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Lancet 1985; 8433: 842-847
• 6 Van de Werf F, Vanhaeck J, De Geest H, Verstraete M, Collen D. Coronary thrombolysis with recombinant single-chain urokinase-type plasminogen activator in patients with acute myocardial infarction. Circulation 1986; 74: 1066-1070
• 7 Been M, De Bono DP, Muir AL, Boulton FE, Fears R, Standring R, Ferres H. Clinical effects and kinetic properties of intravenous APSAC - anisoylated plasminogen-streptokinase activator complex (BRL 26921) in acute myocardial infarction. Int J Cardiol 1986; 11: 53-61
• 8 Sherry S. Recombinant tissue plasminogen activator (rt-PA): is it the thrombolytic agent of choice for an evolving acute myocardial infarction. Am J Cardiol 1987; 59: 984-989
• 9 Van de Werf F, Nobuhara M, Collen D. Coronary thrombolysis with human single-chain, urokinase-type plasminogen activator (prourokinase) in patients with acute myocardial infarction. Ann Intern Med 1986; 104: 345-348
• 10 Collen D, Tygat G, Claeys H, Verstraete M, Wallen P. Metabolism of plasminogen in healthy subjects: effect of tranexamic acid. J Clin Invest 1972; 51: 1310-1318
• 11 Robinson JH, Dodd I. Fibrinolytically active hybrid protein. European Patent Application 1985 EPA 0155387
• 12 Nakayama Y, Miyazaki W, Shinohara M. Urokinase-plasmin complex adsorbable by fibrin and process for preparing same. European Patent Application 1985 EPA 0151308
• 13 Robbins KC, Tanaka Y. Covalent molecular weight ∼92000 hybrid plasminogen activator derived from human plasmin amino-terminal and urokinase carboxy-terminal domains. Biochem 1986; 25: 3603-3611
• 14 Robbins KC, Boreisha IG. A covalent molecular weight ∼92000 hybrid plasminogen activator derived from human plasmin fibrinbinding and tissue plasminogen activator catalytic domains. Biochem 1987; 26: 4661-4667
• 15 Dodd I, Jalalpour S, Southwick W, Newsome P, Browne MJ, Robinson JH. Large scale, rapid purification of recombinant tissue- type plasminogen activator. FEBS Lett 1986; 209: 13-17
• 16 Browne MJ, Dodd I, Carey JE, Chapman CG, Robinson JH. Increased yield of human tissue-type plasminogen activator obtained by means of recombinant DNA technology. Thromb Haemostas 1985; 54: 422-424
• 17 Summaria L, Boreisha I, Wohl RC, Robbins KC. Recombinant human lys-plasmin and the lys-plasmin-streptokinase complex. J Biol Chem 1979; 254: 6811-6814
• 18 Dodd I, Fears R, Robinson JH. Isolation and preliminary characterisation of active B-chain of recombinant tissue-type plasminogen activator. Thromb Haemostas 1986; 55: 94-97
• 19 Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilising the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254
• 20 Smith RA G. An active-site titrant for human tissue-type plasminogen activator. Biochem J 1986; 239: 477-479
• 21 Castellino FJ. Recent advances in the chemistry of the fibrinolytic system. Chem Rev 1981; 81: 431-446
• 22 Verstraete M, Bounameaux H, De CockF, Van deWerf, Collen D. Pharmacokinetics and systemic fibrinogenolytic effects of recombinant human tissue-type plasminogen activator (rt-PA) in humans. J Pharm Exp Ther 1985; 235: 506-512
• 23 Rijken DC, Groenveld E. Isolation and functional characterisation of the heavy and light chains of human tissue-type plasminogen activator. J Biol Chem 1986; 261: 3098-3102
• 24 MacDonald ME, Van Zonneveld A-J, Pannekoek H. Functional analysis of the human tissue-type plasminogen activator protein: the light chain. Gene 1986; 42: 59-67
• 25 Hoylaerts M, Rijken DC, Lijnen HR, Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator. J Biol Chem 1982; 257: 2912-2919
• 26 Dodd I. Degraded species of tissue-type plasminogen activator. European Patent Application 1986 EPA 0196920
• 27 Dodd I, Nunn B, Robinson JH. Isolation, identification and pharmacokinetic properties of human tissue-type plasminogen activator species: possible localisation of a clearance recognition site. Thromb Haemostas 1988; 59: 523-528
• 28 Browne MJ, Carey JE, Chapman CG, Tyrrell AW, Entwisle E, Lawrence GM, Reavy B, Dodd I, Esmail A, Robinson JH. A tissue-type plasminogen activator mutant with prolonged clearance in vivo. J Biol Chem 1988; 263: 1599-1602
• 29 Rijken DC, Emeis JJ. Clearance of the heavy and light polypeptide chains of human tissue-type plasminogen activator in rats. Biochem J 1986; 238: 643-646
• 30 Kalyan NK, Lee SG, Hum W-T, Hartzell R, Levner M, Hung P P. In vitro studies on the binding of tissue-type plasminogen activator (t-PA) and urokinase (u-PA) to liver membranes. Thromb Haemostas 1987; 58: 217 (Abstr)
• 31 Cambier P, Van de Werf F, Larsen GR, Collen D. Coronary thrombolysis in dogs with a nonglycosylated variant of human tissue- type plasminogen activator lacking the finger and growth factor domains. Thromb Haemostas 1987; 58: 217 (Abstr)
• 32 Larsen R, Metzger M, Blue Y, Henson K. Pharmacokinetics of genetically modified t-PA in rat. Thromb Haemostas 1987; 58: 217 (Abstr)
• 33 Kominger C, Stassen JM, Collen D. Turnover of human extrinsic (tissue-type) plasminogen activator in rabbits. Thromb Haemostas 1981; 46: 658-661
• 34 Nunn B, Esmail A, Fears R, Ferres H, Standring R. Pharmacokinetic properties of anisoylated plasminogen streptokinase activator complex and other thrombolytic agents in animals and humans. Drugs 1987; 33 Suppl (Suppl. 03) 88-92
• 35 Lau D, Kuzma G, Wei C-M, Livingston DJ, Hsiung N. A modified human tissue plasminogen activator with extended half-life in vivo. Bio/technology 1987; 5: 953-958
• 36 Stump DC, Kieckens L, De Cock F, Collen D. Pharmacokinetics of single chain forms of urokinase-type plasminogen activator. J Pharm Exp Ther 1987; 242: 245-250
• 37 Ezzell C. US patents in the balance. Nature 1987; 328: 189
• 38 Klausner A. Second-generation t-PA race heats up. Bio/technology 1987; 5: 869-870